Optimal PD-L1-high cutoff for association with overall survival in patients with urothelial cancer treated with durvalumab monotherapy

Studies have indicated that programmed death ligand 1 (PD-L1) expression may have utility as a predictive biomarker in patients with advanced/metastatic urothelial carcinoma (UC). Different immunohistochemical (IHC) assays are in development to assess PD-L1 expression on tumor cells (TCs) and tumor-...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	PloS one 2020-04, Vol.15 (4), p.e0231936-e0231936
Hauptverfasser:	Zajac, Magdalena, Ye, Jiabu, Mukhopadhyay, Pralay, Jin, Xiaoping, Ben, Yong, Antal, Joyce, Gupta, Ashok K, Rebelatto, Marlon C, Williams, J Andrew, Walker, Jill
Format:	Artikel
Sprache:	eng
Schlagworte:	Algorithms Analysis Apoptosis Assaying Biology and Life Sciences Biomarkers Bladder cancer Cancer Cancer patients Cancer therapies Carcinoma Care and treatment Chemotherapy Confidence intervals Durvalumab FDA approval Immune system Immunotherapy Ligands Medical equipment industry Medical research Medicine and Health Sciences Metastases Metastasis Monoclonal antibodies Multivariate analysis Patient outcomes Patients PD-L1 protein Pharmaceutical industry Physical Sciences Research and Analysis Methods Studies Survival Targeted cancer therapy Tumor cells Tumor-infiltrating lymphocytes Tumors Urothelial cancer Urothelial carcinoma
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!